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In this issue of Immunity, Haghikia and colleagues (2015) demonstrate that dietary fatty acids, by modulating
gut microbes and their metabolism, regulate mucosal immune cells to impact systemic immunity. Using this
mechanism, dietary and bacteria-derived medium-chain and long-chain fatty acids exacerbate, whereas
short-chain fatty acids ameliorate, autoimmunity in the brain.Our understanding of the relationship
between us as the host and gut microbes
as the guests has been, and still is, under-
going continuous evolution. For a long
time, we thought of this relationship as
‘‘commensal,’’ meaning that it is a one-
way street with only the microbes as the
beneficiaries of this living-together
arrangement. Nonetheless, why our im-
mune system does not view these mi-
crobes as aliens and tolerates their exis-
tence in our gut without mounting an
overt immune response is still puzzling.
Studies addressing this intriguing ques-
tion have led to the discovery that gut
microbes and their metabolites play an
active role in modulating the mucosal im-
mune system to establish a ‘‘tolerant’’
phenotype, facilitating the continuation
of the co-existence (Ganapathy et al.,
2013; Kim et al., 2014). Bacterial fermen-
tation products, principally short-chain
fatty acids (SCFAs), mediate the effects
of gut microbes on the host immune sys-
tem, regulating the differentiation and
function of almost every cell type in the
immune cell repertoire of the gut. The mo-
lecular mechanisms underlying this pro-
cess involve not only cell-surface recep-
tors such as GPR109A, GPR41, and
GPR43 (Ganapathy et al., 2013; Kim
et al., 2014) but also intracellular targets
such as histone deacetylases (Singh
et al., 2010; Gurav et al., 2015). Subse-
quently it became apparent that the mod-
ulation of the mucosal immune system by
gut microbes is not limited solely to facili-
tation of their co-existence with the host;
it also has significant impact on colonic
health protecting against inflammation
and carcinogenesis. These observations
led to a major paradigm shift in the field,
making it obvious that the relationship be-tween the host and the gutmicrobes is not
‘‘commensal’’ but actually ‘‘symbiotic.’’
Despite this inter-dependent mutually
beneficial relationship, the gut microbes
are still referred often times as ‘‘commen-
sals,’’ thus inadvertently denying them the
well-deserved recognition of their benefi-
cial effects on the host. An important
outcome of this paradigm shift is the
appreciation of the importance of diet in
this process because the constituents of
dietary fiber serve as the raw material for
bacterial fermentation to generate SCFAs
as the effector molecules. Gut microbes
consist of 800–1,000 species with
different metabolic capabilities; they rely
on different constituents of dietary fiber
for fermentation and consequently their
fermentation products vary depending
on the microbial species. As a result,
diet is an important determinant of the
composition of microbial species in the
gut, which differs from individual to indi-
vidual and can be altered in a given
individual. Dysbiosis (i.e., quantitative
changes in relative proportion of different
microbial species, thus altering their
normal balance and their fermentation
products) is often associated with various
intestinal diseases such as inflammatory
bowel disease.
It has become increasingly clear in
recent years that the impact of gut mi-
crobes and their metabolites on the
mucosal immune system has conse-
quences well beyond the local environ-
ment and affects biological processes
elsewhere in the body (Kuhn and Stap-
penbeck, 2013). This is neither surprising
nor unexpected given the fact that the in-
testinal tract harbors almost two-thirds of
the immune cells found in the body and
that these immune cells do not stay stag-Immunity 43nant in the gut but migrate to other parts
of the body, including the brain. As the dif-
ferentiation and function of immune cells
are subject tomodulation by gutmicrobes
while residing in the gut, the subtype and
cytokine profiles of the immune cells that
emigrate from the gut depend on the mi-
crobial composition as well as diet. One
can thus expect dietary constituents and
gut microbes to impact on immune-
related processes outside the gut. Haghi-
kia and colleagues (2015) demonstrate
this phenomenon in the context of auto-
immunity in the central nervous system.
It is already known that diet and gut mi-
crobes influence systemic autoimmune
responses in diseases such as type 1 dia-
betes, rheumatoid arthritis, systemic
lupus erythematosus, and multiple scle-
rosis (Longman and Littman, 2015; Vieira
et al., 2014), but little is known on this phe-
nomenon at molecular level. The study by
Haghikia et al. (2015) delves into the mo-
lecular mechanisms by which gut mi-
crobes and their metabolites impact the
progression of an experimentally induced
T cell-mediated autoimmune disease in
the central nervous system and also into
the role of dietary fatty acids in the pro-
cess. These studies consist of in vitro
and in vivo experiments. There are three
salient features of the in vitro experi-
ments. First, medium-chain fatty acids
(MCFAs; carbon chain length 6–12) and
long-chain fatty acids (LCFAs; carbon
chain length 14–18) promote the differen-
tiation of murine and human CD4+ naive
T cells into T helper 1 (Th1) and Th17 cells
with corresponding production of the
pro-inflammatory cytokines interferon-g
(IFN-g) and interleukin-17A (IL-17A);
MCFAs also suppress the conversion of
CD4+ naive T cells into FOXP3+ regulatory, October 20, 2015 ª2015 Elsevier Inc. 629
Figure 1. Gut Fatty Acids Drive Intestinal T Cell Differentiation that Influences Development
of Autoimmunity in other Distal Tissues
Naive CD4+ T cells that originate in the bone marrow and thymus migrate to the lamina propria of the gut,
where they differentiate into various T helper subtypes under the influence of fatty acids derived from the
diet or bacteria. In the presence of MCFAs or LCFAs, T cell differentiation is skewed toward inflammatory
subtypes (Th1 and Th17), whereas in the presence of SCFAs, differentiation is skewed toward regulatory
subtypes (Treg cells). These fatty-acid-influenced T cells drive pathogenic or protective responses in other
tissues such as the central nervous system and modulate autoimmunity. Abbreviations are as follows:
MCFAs, medium-chain fatty acids; LCFAs, long-chain fatty acids; SCFAs, short-chain fatty acids.
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of the anti-inflammatory cytokine IL-10.
Second, short-chain fatty acids (SCFAs;
carbon chain length 3–4) suppress the
production of Th17 cells and promote
the production of Treg cells from CD4+
naive T cells. Third, MCFAs elicit their ef-
fects via activation of the p38 MAPK
pathway, whereas SCFAs elicit their ef-
fects via activation of lipin2-JIP2 pathway.
These data demonstrate that MCFAs and
LCFAs promote inflammation whereas
SCFA suppress inflammation via their dif-
ferential effects on the differentiation of
naive CD4+ T cells into Th1, Th17, and
Treg cells. The investigators then used a
murine central nervous system autoim-
mune disease model, experimental auto-
immune encephalomyelitis, which is a
surrogate for human multiple sclerosis,
and examined the influence of dietary lau-
ric acid (MCFAs), palmitic acid (LCFAs), or
propionic acid (SCFAs) on the progres-
sion of the disease. The findings of these630 Immunity 43, October 20, 2015 ª2015 Elin vivo experiments include two main
points. First, dietary MCFAs and LCFAs
aggravate the disease progression due
to an increase in Th17 cells in the brain
and spleen, and second, SCFAs amelio-
rate the disease progression as a result
of an increase in Treg cells and IL-10 pro-
duction. The study then focused on the
anatomic site in which dietary fatty acids
elicit their effects in terms of T cell differ-
entiation. These experiments show that
dietary MCFAs increase the amount of
MCFAs and LCFAs but decrease the
amount of SCFAs in the feces along with
an increase in Th1 and Th17 cells in the
lamina propria of the small intestine, and
that these effects are not seen in germ-
freemice. The conclusion of these studies
is that dietary MCFAs and LCFAs modu-
late gut microbes and their metabolism
such that naive CD4+ T cells in the lamina
propria are exposed to increased concen-
trations of MCFAs and LCFAs and
decreased concentrations of SCFAs,sevier Inc.thus tilting the T cell repertoire more to-
ward the pro-inflammatory type and less
toward the immunosuppressive type;
when these cells emigrate from the intes-
tinal tract to the brain, they affect the
progression of autoimmunity (Figure 1).
Taken collectively, these findings demon-
strate an interesting and important role for
bacteria-derived SCFA in autoimmunity;
these bacterial metabolites promote dif-
ferentiation of the CD4+ naive T cells in
the gut into immunosuppressive cell types
and block differentiation into pro-inflam-
matory cell types to guard against autoim-
munity outside the gut.
The exact molecular targets for MCFAs
and LCFAs, and SCFAs to bring about
their differential effects on the differentia-
tion of naive CD4+ T cells remain un-
known. Yes, the studies described by Ha-
ghikia et al. (2015) have shown that
MCFAs and LCFAs act through activation
of p38MAPK and that SCFAs act through
lipin2-JIP2, but what triggers these
signaling pathways upstream when the
naive CD4+ T cells get exposed to the
fatty acids has not been identified.
The authors of the study seem to impli-
cate cell-surface receptors as the most
likely targets. This might well be true, but
the possibility exists that these fatty acids
might elicit their biological effects inde-
pendent of cell-surface receptors.MCFAs
and LCFAs might enter the cells and
modulate signaling pathways via covalent
modification of specific proteins (e.g.,
myristylation, palmitoylation, or stearoyla-
tion) (Magee and Seabra, 2005). This
mechanism as an upstream element for
activation of p38MAPK cannot be entirely
ruled out because dietary lauric acid that
aggravates autoimmunity in the brain
does in fact increase the levels of myristic
acid, palmitic acid, and stearic acid in the
small intestinal mucosa. Similarly, SCFAs
(propionic acid and butyric acid) function
as inhibitors of histone deacetylases inde-
pendent of their known cell-surface re-
ceptors; the involvement of this function
upstreamof lipin2-JIP2 pathway in the ac-
tions of SCFA cannot be ruled out either.
The clinical and therapeutic implica-
tions of this study are readily apparent.
The findings indicate that modification of
gut microbes and their metabolism are
viable targets for treatment of not only
multiple sclerosis but potentially also
other autoimmune diseases. The goal of
such a strategy is to promote generation
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ferentiation of naive CD4+ T cells into Treg
cells and not into Th1 and Th17 cells. This
can be achieved with the use of appro-
priate types of dietary fiber that have the
ability to support the growth and prolifer-
ation of SCFA-producing gut microbes.
Prebiotics such as fructo-oligosaccha-
rides are known to increase the levels of
SCFAs in the gut. Probiotics containing
selective species of bacteria known to
produce SCFAs as themajor fermentation
products can also be used to achieve this
goal. Oral delivery of SCFAs might be
problematic because these fatty acids
are metabolized extensively in the upper
portions of the intestinal tract with only a
minor fraction of the original oral dose
entering the ileum and colon wheremajor-
ity of mucosal immune cells reside. But,
SCFAs can be chemically modified
(e.g., SCFAs esterified to starch) andthen administered orally, an approach
that is likely to result in delivery of appre-
ciable amounts of SCFAs to the distal
portions of the intestinal tract. The studies
by Haghikia and colleagues (2015) pro-
vide convincing evidence in support of
therapeutic potential of such approaches
for prevention and/or treatment of autoim-
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Predicting cancer patients’ response to therapy is essential for curing disease and improving quality of life.
Garraway and colleagues demonstrate that the frequency and number of neoantigens, non-synonymous
mutations, and adaptive immune genes, but not the assessment of individual recurrent neoantigens or mu-
tations, predicts patient responses to immunotherapy.The recent success of immunotherapies
targeting immune-checkpoint molecules
cytotoxic T lymphocyte-associated anti-
gen-4 (CTLA4), programmed cell death-
1 (PD-1), and programmed cell death li-
gands (PD-L1 and PDL-2) in the treatment
of cancer has emphasized the essential
role of the immune system in the eradica-
tion of tumors. Although these immuno-
therapies have had stunning results, the
percentage of patients who see a clinical
benefit is limited, and the factors that
determine whether a patient will have animproved clinical response are not well
understood. The ability to predict whether
a patient will respond or become resistant
to immunotherapy is essential for finding a
cure for cancer.
One approach to finding new cancer-
response biomarkers is identifying anti-
gens that are unique to tumors. An
example of these are neoantigens, which
are mutated peptides that arise in tumors
and thus are not present in the normal
genome (Schumacher and Schreiber,
2015). Identifying novel neoantigens hasrecently become more feasible with
whole-exome sequencing. Researchers
use RNA sequencing of tumors to identify
mutations in expressed genes. They can
then process these data in silico to iden-
tify biologically likely peptide-MHC com-
binations. It is hypothesized that more
immunogenic tumor types have higher
rates of somatic mutation and therefore
elevated numbers of neoantigens (Schu-
macher and Schreiber, 2015).
In a recent issue of Science, Van Allen
et al. describe extensive analysis of, October 20, 2015 ª2015 Elsevier Inc. 631
